GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changchun BCHT Biotechnology Co (SHSE:688276) » Definitions » Debt-to-Revenue

Changchun BCHT Biotechnology Co (SHSE:688276) Debt-to-Revenue : 0.06 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Changchun BCHT Biotechnology Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Changchun BCHT Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥65 Mil. Changchun BCHT Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0 Mil. Changchun BCHT Biotechnology Co's annualized Revenue for the quarter that ended in Mar. 2024 was ¥1,081 Mil. Changchun BCHT Biotechnology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.06.


Changchun BCHT Biotechnology Co Debt-to-Revenue Historical Data

The historical data trend for Changchun BCHT Biotechnology Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changchun BCHT Biotechnology Co Debt-to-Revenue Chart

Changchun BCHT Biotechnology Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 0.17 - - - 0.01

Changchun BCHT Biotechnology Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 - 0.01 0.06

Competitive Comparison of Changchun BCHT Biotechnology Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Changchun BCHT Biotechnology Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Changchun BCHT Biotechnology Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changchun BCHT Biotechnology Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Changchun BCHT Biotechnology Co's Debt-to-Revenue falls into.



Changchun BCHT Biotechnology Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Changchun BCHT Biotechnology Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(20.472 + 0) / 1824.689
=0.01

Changchun BCHT Biotechnology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(65.404 + 0) / 1081.152
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Changchun BCHT Biotechnology Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Changchun BCHT Biotechnology Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Changchun BCHT Biotechnology Co (SHSE:688276) Business Description

Traded in Other Exchanges
N/A
Address
No. 1260, Huoju Road, High-tech Development Zone, Jilin Province, Changchun, CHN, 130012
Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.
Executives
Shi Nian Min Core technical personnel
Jiang Chun Lai Directors, senior managers, core technical personn
Zhu Chang Lin Core technical personnel
Wei Wei Senior management, core technical personnel
Yu Bing senior management
Liu Da Wei Senior management, core technical personnel
Meng Zhao Feng senior management
Zhang Zhe senior management
Kong Wei Directors, senior managers, core technical personn
Feng Da Qiang Supervisors

Changchun BCHT Biotechnology Co (SHSE:688276) Headlines

No Headlines